We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-4.41%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.21B
AUM Growth
-$804M
Cap. Flow
-$184M
Cap. Flow %
-2.96%
Top 10 Hldgs %
40.63%
Holding
166
New
10
Increased
38
Reduced
80
Closed
12

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$32.4M
2
UNH icon
UnitedHealth
UNH
+$23.7M
3
CI icon
Cigna
CI
+$21.4M
4
HUM icon
Humana
HUM
+$20.1M
5
APLS
Apellis Pharmaceuticals
APLS
+$12.1M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$72.3M
2
MDT icon
Medtronic
MDT
+$64.4M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$33M
4
CRL icon
Charles River Laboratories
CRL
+$17.5M
5
TMO icon
Thermo Fisher Scientific
TMO
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.13%
2 Industrials 0.77%
3 Energy 0.04%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BEAM icon
76
Beam Therapeutics
BEAM
$2.75B
$16.7M 0.27%
694,821
-600
-0.1% -$16.1K
SUPN icon
77
Supernus Pharmaceuticals
SUPN
$2.82B
$16M 0.26%
580,600
-69,656
-11% -$2.12M
PNT
78
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$15.7M 0.25%
2,351,160
+1,094,963
+87% +$9.1M
SRRK icon
79
Scholar Rock
SRRK
$6.24B
$15.2M 0.24%
2,137,925
-2,100
-0.1% -$14.1K
INSP icon
80
Inspire Medical Systems
INSP
$1.48B
$14M 0.23%
70,368
-286,652
-80% -$72.3M
VRNA
81
DELISTED
Verona Pharma
VRNA
$14M 0.22%
856,358
+284,043
+50% +$5.47M
GBIO
82
DELISTED
Generation Bio
GBIO
$13.7M 0.22%
361,708
-320
-0.1% -$15.2K
AMGN icon
83
Amgen
AMGN
$198B
$13M 0.21%
48,473
+21,163
+77% +$5.28M
REGN icon
84
Regeneron Pharmaceuticals
REGN
$70.7B
$12.3M 0.2%
14,939
-1,388
-9% -$1.09M
TXG icon
85
10x Genomics
TXG
$5.4B
$12.1M 0.2%
294,432
-30,314
-9% -$1.58M
NTRA icon
86
Natera
NTRA
$37.8B
$11.4M 0.18%
257,686
+24,911
+11% +$1.27M
RMD icon
87
ResMed
RMD
$28.4B
$11.3M 0.18%
76,696
-21,579
-22% -$3.9M
PHR icon
88
Phreesia
PHR
$651M
$10.8M 0.17%
579,039
-59,614
-9% -$1.6M
OMCL icon
89
Omnicell
OMCL
$2.08B
$10.8M 0.17%
239,279
-54,066
-18% -$3.28M
FATE icon
90
Fate Therapeutics
FATE
$328M
$10.3M 0.17%
4,851,579
-4,200
-0.1% -$13.9K
AMED
91
DELISTED
Amedisys
AMED
$9.94M 0.16%
106,387
-127,931
-55% -$11.8M
ILMN icon
92
Illumina
ILMN
$27.9B
$9.89M 0.16%
74,047
-12,332
-14% -$2.03M
ONC
93
BeOne Medicines Ltd
ONC
$32.5B
$9.5M 0.15%
53,200
+43,000
+422% +$8.51M
DOCS icon
94
Doximity
DOCS
$3.84B
$8.48M 0.14%
399,457
-49,122
-11% -$1.34M
GILD icon
95
Gilead Sciences
GILD
$166B
$8.04M 0.13%
107,350
-5,300
-5% -$408K
MRSN
96
DELISTED
Mersana Therapeutics
MRSN
$6.63M 0.11%
208,745
-32
-0% -$1.52K
TDOC icon
97
Teladoc Health
TDOC
$1.68B
$6.61M 0.11%
355,649
-36,615
-9% -$855K
MTEM
98
DELISTED
Molecular Templates, Inc.
MTEM
$6.52M 0.11%
1,031,613
+282,946
+38% +$2.25M
AZN icon
99
AstraZeneca
AZN
$260B
$5.73M 0.09%
42,300
-500
-1% -$68.3K
RDY icon
100
Dr. Reddy's Laboratories
RDY
$10.5B
$5.41M 0.09%
401,000
-57,500
-13% -$778K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2023 Portfolio in Review

As of Q3 2023, Bellevue Group held 166 positions worth $6.21B, down 11% from $7.01B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q3 2023 filing shows 10 new, 38 increased, 80 reduced and 12 closed positions. Its largest new stake was Viatris: 176,848 shares worth $1.74M. The largest sale was Inspire Medical Systems, an estimated $72.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q3 2023 buy was Viatris: 176,848 shares worth $1.74M.
  • Bellevue Group added most to Elevance Health in Q3 2023, an estimated $32.4M increase.
  • Bellevue Group's biggest Q3 2023 reduction was Inspire Medical Systems, cutting an estimated $72.3M.
  • Bellevue Group fully exited Baxter International in Q3 2023, selling an estimated $9.72M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.21B portfolio in Q3 2023.
  • Bellevue Group opened 10 new positions and closed 12 in Q3 2023.
  • Bellevue Group's portfolio value fell 11% quarter-over-quarter to $6.21B.

Based on Bellevue Group's 13F filing for Q3 2023, filed 14 Nov 2023.